Oxigene has successfully completed patient enrollment in a Phase II clinical trial for the treatment of imageable solid tumors. The trial, which is being conducted in the U.S. under an investigational new drug (IND) application on file with the FDA, is designed to evaluate the safety and anticancer activity of the triple combination of Combretastatin A4P (CA4P) together with widely-used chemotherapy agents, carboplatin and paclitaxel. OXiGENE expects the presentation of top line data later in 2006, as patients enrolled in this trial are continuing to receive prolonged therapy.
The Phase II clinical trial is a randomized, open-label trial designed to evaluate the triple combination of Combretastatin A4P, carboplatin and paclitaxel in patients with solid tumors. The objectives of the trial are to assess the safety of several doses of CA4P in combination with the two chemotherapeutic agents, gather data on anti-tumor activity and establish a recommended Phase II/III dose.